Etoposide and cisplatin combination chemotherapy in extensive stage small cell lung cancer.
- Author:
Jung Yul SUH
1
;
Hyun Sik JEONG
;
Seung Sei LEE
Author Information
1. Department of Internal Medicine, Sungkyunkwan University School of Medicine Kangbuk Samsung Hospital.
- Publication Type:Original Article
- Keywords:
Small Cell Lung Cancer;
Etoposide;
Cisplatin
- MeSH:
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide*;
Humans;
Male;
Prognosis;
Small Cell Lung Carcinoma*
- From:Korean Journal of Medicine
2001;61(6):590-596
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Small cell lung cancer (SCLC) disseminates early and has poor prognosis. However, SCLC is highly chemosensitive, thus chemotherapy has been established as the primary mode of treatment. This study evaluated the efficacy and toxicity of etoposide in combination with cisplatin in the treatment of extensive stage small cell lung cancer. METHODS: Thirty four patients (28 males, 6 females) with previously untreated extensive stage small cell lung cancer were treated with etoposide at a dose of 100 mg/m2, IV on days 1-3 with cisplatin at 100 mg/m2, IV on day 1. The median age was 63 (range 41~80). This combination chemotherapy was administered every 3-4 weeks. Response rate, response duration, survival, and toxicity were evaluated. RESULTS: The response rate was 50%. The median survival time was 29 weeks. The median response duration was 17.2 weeks in responders. The toxicity was acceptable. CONCLUSION: This study illustrated that the combination of etoposide and cisplatin is effective in the treatment of extensive stage small cell lung cancer, and can be administered with acceptable toxicity. Although this study was not designed to be a formal comparative trial, the efficacy and toxicity observed with this regimen were found to be comparable to previous reports.
